Alembic Pharma (Large Cap - High Growth) Share Target 2024, 2025 To 2039
|
Alembic Pharmaceuticals Limited |
|||
|
Price: ₹1,055.15 | ||
| 52 Week Low: ₹746.00 52 Week High: ₹1,303.90 |
|||
| Market Capital: 20,176.07 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Alembic Pharma Share Price Target For 2024
- 1.1.1: Alembic Pharma Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Alembic Pharma Share Price Target For 2025
- 1.2.1: Alembic Pharma Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Alembic Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Alembic Pharma Brief Company Overview
- 4: Alembic Pharma Financial Performance
- 4.0.1: Is Alembic Pharma A Good Buy For Long Term?
To predict the Alembic Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Alembic Pharma Share Price Target For 2024
The line chart displays the monthly closing prices of Alembic Pharma with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alembic Pharma shares in 2024, see the table below.
Alembic Pharma Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1087.84 (+3.09%) | Price Action: 28 Oct 2024 High |
| 2024 Target 2 | 1076.4 (+2.01%) | Price Action: 05 Dec 2024 Low |
| 2024 Target 1 | 1061.85 (+0.63%) | Price Action: 17 Dec 2024 High |
| Current Price | 1055.15 | Alembic Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1040.0 (-1.44%) | Price Action: Sep 2024 Low |
| Stop Loss 2 | 1027.9 (-2.59%) | Price Action: Oct 2024 Low |
| Stop Loss 3 | 994.2 (-5.78%) | Fibonacci Retracement Level 40.00% |
Short-Term Technical Outlook
Current Technical Position: Alembic Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹1070.01 serves as the nearest technical reference point.
Historical Returns: 3-month: -12.47% | 6-month: +21.73% | 1-year: +40.51%
Alembic Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Alembic Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alembic Pharma shares in 2025, see the table below.
Alembic Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1466.99 (+39.03%) | Price Action: Chart |
| 2025 Target 2 | 1439.64 (+36.43%) | Fibonacci Extension Level 123.60% |
| 2025 Target 1 | 1421.29 (+34.70%) | Fibonacci Extension Level 64.90% |
| Current Price | 1055.15 | Alembic Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 945.47 (-10.40%) | Price Action: Sep 2020 High |
| Stop Loss 2 | 933.27 (-11.56%) | Price Action: Jun 2020 High |
| Stop Loss 3 | 923.09 (-12.52%) | Price Action: Feb 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Alembic Pharma is currently trading at 55.4% of its 52-week range (₹746 - ₹1303.9).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +40.51% | 3-year: +36.61% | 5-year: +96.97%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Alembic Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,055.15 | ||
| 2024 | ₹1,136.64 | +7.72% | ₹1,153.69 |
| 2025 | ₹1,400.56 | +23.22% | ₹1,421.57 |
| 2026 | ₹1,559.31 | +11.33% | ₹1,582.70 |
| 2027 | ₹1,755.22 | +12.56% | ₹1,781.55 |
| 2028 | ₹1,908.60 | +8.74% | ₹1,937.23 |
| 2029 | ₹2,111.68 | +10.64% | ₹2,169.69 |
| 2030 | ₹2,426.06 | +14.89% | ₹2,462.45 |
| 2031 | ₹2,555.22 | +5.32% | ₹2,593.55 |
| 2032 | ₹2,749.27 | +7.59% | ₹2,790.51 |
| 2033 | ₹2,879.54 | +4.74% | ₹2,938.81 |
| 2034 | ₹3,086.73 | +7.20% | ₹3,195.19 |
| 2035 | ₹3,451.57 | +11.82% | ₹3,503.34 |
| 2036 | ₹3,551.12 | +2.88% | ₹3,604.39 |
| 2037 | ₹3,743.33 | +5.41% | ₹3,799.48 |
| 2038 | ₹3,850.48 | +2.86% | ₹3,964.32 |
| 2039 | ₹4,055.88 | +5.33% | ₹4,220.70 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Alembic Pharma Brief Company Overview
Alembic Pharmaceuticals Limited: A Trusted Name in Pharmaceuticals Established in 1907, Alembic Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global footprint. The company offers a diverse range of branded specialty medicines in areas such as...
cardiology, gynecology, and ophthalmology. It also manufactures generic formulations in various categories, including oral solids, injectables, and ophthalmic products. Reputation: Alembic Pharmaceuticals Limited enjoys a strong reputation for quality and innovation within the industry. Commitment: The company is committed to providing affordable and accessible healthcare solutions to patients worldwide.Alembic Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 20,176.07 Crore | Market valuation of Alembic Pharma's shares. |
| Revenue (TTM) | 6,357.25 Crore | Total revenue generated by Alembic Pharma over the past twelve months. |
| Net Income (TTM) | +6,467,800,064.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +10.24% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +10.17% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+3.30% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+12.30% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
21.81 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1,066.34 Crore | Sum of Alembic Pharma's current & long-term financial obligations. |
| Total Cash | 128.95 Crore | Total amount of liquid funds available to Alembic Pharma. |
| Beta | 0.69 | Beta is less than 1 indicating that the Alembic Pharma's price is less volatile than the market. |
Is Alembic Pharma A Good Buy For Long Term?
Alembic Pharma (market cap: ₹20,176.07 Crore) shows mixed signals. While its strong revenue (₹6,357.25 Crore) and impressive 12-month return (46.11%) are positive, a debt of ₹1,066.34 Crore (Q2 2024-25) needs consideration. The 10.17% profit margin and recent 3-month decline (-11.68%) temper enthusiasm. Long-term prospects depend on debt management and sustained revenue growth. Therefore, Alembic Pharma is an average buy for long-term investors, warranting further in-depth analysis before a final decision.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
